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Abstract
Background Contrast-induced nephropathy (CIN), an
acute kidney injury resulting from the administration of
intravascular iodinated contrast media, is an important
cause of morbidity/mortality following coronary angio-
graphic procedures in high-risk patients. Despite preven-
tative measures intended to mitigate the risk of CIN, there
remains a need for an effective intervention. Remote
ischaemic conditioning (RIC), where non-injurious
ischaemia is applied to an arm prior to the administration
of contrast, has shown promise in attenuating CIN but its
effectiveness in preserving long-term renal function is
unknown, which will be studied as part of the effect of
remote ischaemic conditioning against contrast-induced
nephropathy (ERICCIN) trial. (http://Controlled-trials.com
Identifier: ISRCTN49645414.)
Methods The ERICCIN trial is a single-centre, random-
ised double-blinded placebo-controlled trial which plans to
recruit 362 patients who are at risk of CIN, defined by pre-
existent renal impairment (estimated glomerular filtration
rate \60 ml/min/1.73 m2), over a period of 2 years.
Patients will be randomised to either control or RIC
consisting of 4, 5 min 200 mmHg balloon-cuff inflation/
deflations, to the upper arm. The primary endpoint will be
the development of CIN ([25 % of eGFR, or rise of cre-
atinine of [44 lmol/l) at 48 h. A key secondary endpoint
will be whether RIC impacts upon persistent renal
impairment over the 3-month follow-up period. Additional
secondary endpoints include the measurement of serum
neutrophil gelatinase-associated lipocalin and urinary
albumin at 6, 48 h and 3 months following administration
of contrast.
Implications Findings from ERICCIN trial will poten-
tially demonstrate that RIC attenuates contrast-induced
acute and chronic kidney injury and influence future clin-
ical practice guidelines in at-risk patients undergoing cor-
onary angiographic procedures.
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Background
Contrast-induced nephropathy (CIN) is an acute, iatro-
genic kidney injury triggered by the intravascular
administration of iodinated contrast agents. Defined as a
25 % rise or an absolute 0.5 mg/dl (44 lmol/L) increase
in serum creatinine within 72 h of contrast exposure, in
the absence of an alternative explanation [1], CIN is an
important clinical problem following angiography and
percutaneous intervention. It represents the third most
common cause of hospital-acquired acute renal failure [2,
3] and is associated with significant mortality and mor-
bidity, with up to 19 % of those suffering CIN developing
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persistent renal impairment months after contrast media
exposure [4]. With the incidence of renal replacement
therapy estimated at 0.2 % [5], the attendant healthcare
costs associated with CIN are substantial [5]. Moderate to
severe chronic renal impairment (estimated glomerular
filtration (eGFR) \60 ml/min or a creatinine of
[120 mmol/L; National Kidney Foundation chronic kid-
ney disease (CKD) stages 3 and 4 [6]) is regarded as the
most important risk factor in the development of CIN [7],
but other risk factors such as diabetes, reduced left ven-
tricular systolic function, advancing age, concomitant use
of nephrotoxic drugs, large contrast agent volumes, in-
traprocedural hypotension and either high or low haema-
tocrits (dehydration/anaemia) are also well recognised [8].
Due to the association between renal and cardiovascular
disease, patients with CIN risk factors are common within
the cohort of patients requiring an angiographic inter-
vention and, despite the introduction of a number of
prophylactic measures, the incidence of CIN remains
unacceptably high. In the CARE study, the incidence of
CIN despite optimal medical therapy remained between
10 and 15 % [9]. The notion of optimal medical care in
this patient cohort remains hotly contested. There are a
number of national and international guidelines and all
recommend avoidance of nephrotoxic drugs, adequate pre-
hydration and the use of low- or iso-osmolar contrast
agents. The augmentation of pre-hydration with antioxi-
dants or alkalinizers such as N-acetyl cysteine and sodium
bicarbonate, respectively, remain hotly contested, but
recent meta-analyses appear to suggest a small advantage
towards bicarbonate pre-hydration over N-acetylcysteine
[10]. Given a lack of clarity regarding the most effica-
cious intervention against CIN, a large, multicentre ran-
domised control study has started recruiting (target 8,680
patients, the prevention of serious adverse events fol-
lowing angiography (PRESERVE) trial [11]), the results
of which will hopefully help to clarify optimal preparation
of patients at risk of CIN. Similarly, there is debate over
which contrast media is the least injurious to the at-risk
kidney. The landmark comparison trial between iso-
osmolar iodixanol and the low-osmolar iohexol contrast
media by Chalmers and Jackson in 1999, which demon-
strated a modest superiority for iodixanol, has been a
powerful influence on subsequent contrast media decision-
making, although more recent meta-analyses seem to
suggest parity of risk between iso-osmolar and the
majority of low-osmolar contrast media [12–16]. The lack
of clear evidence of one intervention over another appears
to suggest one thing: the lack of a single successful
intervention to prevent CIN. There is, therefore, a clear
clinical need for an effective intervention that can reduce
the incidence of CIN following angiographic and other
iodinated contrast requiring procedures.
While the pathophysiology of contrast-induced renal
injury remains the subject of on-going basic research, one
of the principal mechanisms for acute contrast nephropathy
is thought to be vaso-constrictive renal hypoxic injury and
release of reactive oxygen species (ROS) [17]. Such an
injury is likely to be mediated by cell-death signalling of
the type found in many other organ systems typified by
lethal reperfusion injury [18]—and as such may be ame-
nable to interventions such as ischaemic preconditioning
(see review [19]). Interestingly, the potential of remote
ischaemic conditioning was highlighted in a retrospective
study by Whittaker and Przyklenk [20], and more recently
three prospective trials have been published to support the
supposition of remote renoprotection. In the first, Er et al.
demonstrated in a small (n = 50/group) proof-of-concept
trial that remote ischaemic conditioning (RIC), consisting
of 4 cycles of 5 min ischaemia/5 min reperfusion of the
upper limb by inflation/deflation of a blood pressure cuff
prior to contrast exposure, was effective in significantly
reducing the rate of CIN from 40 % in controls to 12 %
[21]. The second, Deftereos et al. recruited 225 non-ST
elevation myocardial infarction (NSTEMI) patients to
receive either sham or an ischaemic conditioning stimulus
consisting of 4, 30 s ischaemia/30 s reperfusion cycles by
inflation/deflation of an intracoronary balloon following
intervention upon the culprit lesion; consistent with upper
limb RIC, they demonstrated that intracoronary RIC
reduced the rate of CIN from 29.5 % in control to 12.4 %
[22]. The third, Igarashi et al. [23], using an identical
conditioning regime to that used by Er et al. and, utilising a
novel bio-marker, urinary liver-type fatty acid-binding
protein (L-FABP) as a primary endpoint, demonstrated a
significant reduction of CIN from 26.9 to 7.7 % in the
remote ischaemic preconditioned group. Although a small
trial (n = 20 per group), there was an attempt to uncover
the mechanism of contrast media renal injury, with the
demonstration of attenuated oxidative stress as measured
by derivatives of reactive oxidative metabolite (D-ROM)
levels and reduced asymmetrical dimethylarginine
(ADMA), an endogenous inhibitor of nitric oxide synthase
following remote ischaemic preconditioning. These data
are encouraging, but there is a need for further evidence
before routine medical practice can be altered. These pre-
vious proof-of-concept trials have been small and relatively
limited in scope, concentrating primarily upon the inci-
dence of acute kidney injury and have not looked at the
longer-term sequelae of that renal injury in terms of per-
sistent renal damage. As noted above, CIN is not a purely
transient phenomenon; it frequently has long-term serious
sequelae with persistent kidney damage evident in a fifth of
those with an acute biochemical manifestation of CIN [4].
The effect of remote ischaemic conditioning against con-
trast-induced nephropathy (ERICCIN) trial is therefore
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designed to evaluate RIC against CIN in elective angiog-
raphy/PCI, and to ascertain the longer-term efficacy in
terms of prevention of persistent renal injury at 3 months
determined by serum creatinine/estimate glomerular fil-
tration rate and development of proteinuria, a known
consequence of CIN [24] and a portent for increasing
cardiovascular risk and all-cause mortality [25].
Methods
Study objectives
The primary objective of this study is to determine whether
remote ischaemic conditioning attenuates the rate of CIN
arising from the administration of iodinated intracoronary
contrast as part of routine and semi-emergent (NSTEMI)
coronary artery angiography/percutaneous intervention.
The study will ascertain whether acute injury at 48 h fol-
lowing the administration of contrast, as determined by
serum creatinine, serum neutrophil gelatinase-associated
lipocalin (NGAL, determined by both laboratory and point-
of-care testing) and new-onset proteinuria, is attenuated by
remote ischaemic conditioning. The study will also seek to
ascertain whether attenuation of contrast-induced
nephropathy results in chronic kidney damage defined by
persistently depressed glomerular filtration rate and
increased or new-onset proteinuria.
Study design
The study has received Ethical Committee approval
(National Research Ethics Service Committee, London-
Queen Square; REC reference 13/LO/0502). The ERICCIN
trial is a placebo-controlled, single-centre double-blind
proof-of-concept study. It investigates the effect of remote
ischaemic conditioning upon acute renal injury at 48 h and
as a secondary endpoint, to determine whether it impacts
upon long-term renal function 3 months post-procedure.
Study population
The investigators will seek to recruit patients aged between
18 and 85 years of age and scheduled for any Cardiac
Catheter Laboratory investigation that involves the
administration of intracoronary iodinated contrast at the
Heart Hospital, UCLH NHS Trust (Fig. 1). The patients
recruited will have an estimated glomerular filtration rate
(as estimated using the modification of diet in renal disease
(MDRD) formula [26]) of less than 60 ml/min/1.73 m2 and
will have freely given informed consent. Patients excluded
from the trial will fall outside these pre-requisites, and in
addition will have one or more of the following exclusion
criteria: pregnancy; end-stage renal failure and on dialysis;
coagulopathy with an INR [2.0; recent intravenous or
intra-arterial iodinated contrast exposure within the previ-
ous 4 weeks; any contraindication for balloon-cuff inflation
or have presented as an ST elevation myocardial infarction,
cardiac arrest or are in cardiogenic shock.
The study will conform to the spirit and letter of the
declaration of Helsinki and in accordance with the UCL
Good Clinical Practice Guidelines.
Intervention
The remote ischaemic conditioning intervention will be
undertaken within 2 h prior to the administration of
iodinated contrast media. Those patients randomised to
receive RIC will have a standard blood pressure cuff placed
on the upper arm. The administration of the intervention
will be via the automated delivery of four cycles of
200 mmHg blood pressure cuff inflation for 5 min fol-
lowed by cuff deflation for 5 min, using a laptop-controlled
device developed and purpose built within the department
of Medical Physics and Bioengineering at UCL. The pla-
cebo group will receive a sham protocol similar to RIC, but
rather than the cuff being inflated to 200 mmHg to induce
transient limb ischaemia, the cuff is instead inflated to a
non-occlusive 10 mmHg to provide the impression of a
treatment being administered.
Randomisation and allocation
On the day of the angiographic procedure, the patients will
be randomised to one of two groups: remote ischaemic
conditioning or control, using minimization for CIN risk
factors in a 1:1 ratio. The minimization criteria are those
factors which predict the risk of acute kidney injury: eGFR
(\20, 20–40, 40–60 ml/min), age (\75, [75 year), diabe-
tes, NYHA III/IV heart failure and haematocrit (\0.39,
[0.39) as identified by Mehran et al. [8], and whether the
patient is undergoing bi-ventricular device implantation, a
recognised high-risk group for CIN [27]. This will ensure
that the study and placebo groups are evenly matched in
terms of the pre-procedure risk of CIN. Randomisation will
be performed by a non-blinded cardiac research nurse
using a freeware computer programme (MinimPy 0.3).
Study endpoints
Primary clinical endpoint
The primary endpoint of the trial will be the incidence of
contrast-induced nephropathy, as defined biochemically
by a 25 % increase or an absolute rise of 0.5 mg/dl
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(44 lmol/l) from baseline in serum creatinine 48 h fol-
lowing contrast medium exposure.
Secondary clinical endpoints
The secondary endpoint of the study will be the demonstration
of a persistent benefit of the RIC intervention against long-
term renal impairment. The renal function will be determined
by biochemical markers: creatinine, eGFR and serum NGAL
from baseline at 6, 48 h and 3 months post-contrast exposure.
These data will be further supported by the measurement
urinary albumin (dipstick and Albumin:Creatinine ratio) from
baseline at 48 h and 3 months post-contrast medium exposure
as a measure of renal tubular function.
In addition to biochemical assessment of renal function,
for all groups the cardiovascular endpoints include death,
non-fatal MI, revascularisation, acute heart failure, non-
fatal stroke, major haemorrhage, rehospitalisation,
haemofiltration or haemodialysis during 3 months follow-
up will also be recorded.
Sample size calculation
There will be two arms to the ERICCIN trial: placebo
control and remote ischaemic conditioning. We plan to
recruit 362 patients (181 per arm of the study), undergoing
angiographic procedures at the Heart Hospital, UCL. The
rate of CIN in previous trials has ranged from 7 % [8] to
40 % [21] (Table 1), with a mean and median reported rate
of CIN of 19 and 17 %, respectively. These data are in-line
with our own audit data of 1,913 patients undergoing
angiographic procedures at the Heart Hospital over the
period of 1st June 2011 to the 30th June 2012, revealing a
rate of CIN of 22 % over the study period (unpublished
data). For our study calculations, we proposed a CIN
incidence of 15 %.
Fig. 1 Flow diagram showing
the recruitment and design of
the ERICCIN trial. Patients
meeting the inclusion criteria,
and having provided informed
consent are then randomised to
either placebo (non-occlusive
low-pressure inflation of the
blood pressure cuff to
15 mmHg) or treatment with
RIC (200 mmHg cuff-inflation).
Each 5 min inflation/5 min
deflation is repeated over 4
cycles. Blood samples are
drawn for biochemical
assessment at baseline (pre-
treatment), at 6 h, at 48 h and at
3 months. At these time points,
urine samples are also taken for
urinary protein assessment
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Two previous studies have evaluated RIPC and its effect
on CIN, reporting between 58 % [22] and 70 % [21]
reduction of acute kidney injury. For our power calcula-
tions, we have proposed an effect at the lower end of this
range, and have powered our study to determine a differ-
ence of 60 %. For a power of 80 % and a significance level
of 0.05, we would need to recruit 181 patients into each
trial arm, 362 patients in total.
Statistical analysis
The effect of remote ischaemic conditioning on CIN will
be evaluated using logistic regression. This will be adjusted
for the minimization factors, as well as other covariates of
interest (gender, volume/type of contrast, peri-procedural
hypotension and intra-arterial balloon pump use).
The effect of RIPC treatment on serum creatinine, eGFR
and urine ACR compared with baseline, at 48 h and
3 months will be evaluated using a repeated measures
mixed effects model. The effect on serum NGAL compared
with baseline at 6, 48 h and 3 months will be evaluated
using the same model. The treatment effect will be adjusted
for minimization factors and other covariates of interest
(gender, volume/type of contrast, peri-procedural hypo-
tension and intra-arterial balloon pump use.) A Bonferroni
correction will be applied to eGFR ranges (\20, 20–40,
40–60 ml/min). The data analysis will be performed in a
blinded fashion, on an intention-to-treat basis.
Study monitoring
A data monitoring committee (DMC) will be responsible
for an interim review of the study with regards to whether
the study is appropriately powered and to determine any
significant unforeseen adverse events, especially with
respect to the effect of blood pressure cuff inflation in high-
risk groups. This interim review will performed at a 6 to
12-month time-point and the minutes of all DMC meetings
will be shared with the Research Ethics Committee (REC).
Discussion
The ERICCIN trial is intended to investigate whether RIC,
a simple non-invasive and low-cost intervention, can sig-
nificantly reduce the rate of CIN in patients undergoing
elective and semi-emergent coronary angiographic proce-
dures, and whether improvement in biochemical markers
are related to a persisting benefit in terms of renal function
measured after 3 months of follow-up.
RIC has the potential to meet an unmet clinical need:
current recommendations of using pre-hydration with N-
acetyl cysteine and/or sodium bicarbonate and the use of
iso-osmolar contrast media are presently best practice, and
yet there remains a significant rate of contrast-induced
nephropathy: Mehran and colleagues [8] report rates of
between 7.5 and 57.3 % dependent upon the risk profile of
the patients studied. Even where medical management is
optimised, as was the case in the CARE [9] and REME-
DIAL [28] studies, the overall rate of CIN remains high at
around 10 %. RIC, however, has the prospect of signifi-
cantly attenuating the rate of CIN. Three recent studies,
using either arm-cuff RIC [21, 23] or intermittent cardiac
RIC by intermittently inflating the catheter balloon in
patients managed for non-ST elevation myocardial infarc-
tion [22], have shown promise in terms of attenuating the
rate of CIN, reducing the rate of acute kidney injury by up
to 60 %. Similarly favourable data have been seen using
pharmacological conditioning, with iloprost administration
reducing the rate of CIN by 68 % [29]. Therefore, condi-
tioning appears to offer what cardiologists have been
seeking: an effective intervention against CIN. The three
existing RIC trials were small, particularly the two studies
using balloon-cuff inflation as their conditioning signal [21,
23], and two had surprisingly high rates of CIN (40 % [21],
29.5 % [22], respectively), which most likely, is related to
the risk profile of the patients recruited at the respective
institutions. Therefore, there is a need for additional clin-
ical trials that reflect all-comer, lower-risk patient popula-
tions that are typical of the general cardiology population,
before moving to larger, multicentre, morbidity and mor-
tality outcome trials. Moreover, data showing a persistent
benefit on preserving renal function is lacking, and it is
these gaps in our knowledge that the ERICCIN trial aims to
bridge.
Table 1 Summary of CIN incidence in published clinical trials
Study Number of
patients
recruited
Incidence of contrast
nephropathy in control
group (%)
RenPro [21] 100 40
Renoprotective effect of
RIC [22]
225 29.5
Iloprost prevents CIN [29] 208 22
Cystatin-C and CI-AKI
[35]
410 21.2
Persistent renal damage
after CI-AKI [4]
3,986 12.1
CARE study [9] 482 10
REMEDIAL trial [28] 326 9.9
Urinary IL-18 and NGAL
as early predictive
markers [36]
150 8.7
Citations are listed in order of cited CIN incidence
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The biomarkers used in the present study are renal
function, determined by eGFR/creatinine, serum NGAL
and proteinuria, the latter determined both by the use of a
simple and cheap urinary dip-stick and a urinary albu-
min:creatinine ratio. ERICCIN will be the first RIC trial to
determine long-term (3 month) renal function following
the initial early monitoring period between 48 and 72 h
post-contrast exposure. This will enable us to determine the
rate of persistent renal dysfunction as identified by Maioli
et al. [4], and whether this rate of persistent renal dys-
function is ameliorated by RIC. NGAL is an emerging
biomarker of acute kidney injury, with equivalent increases
of both urinary and plasma NGAL within 6 h of renal the
insult [30], a time course that, should it be reciprocated in
angiographic patients, could influence hospital discharge
decisions on patients admitted for day-case angiographic
procedures. Proteinuria is, in itself, a risk factor for the
onset of CIN [31]. Moreover, the onset and persistence of
proteinuria is a recognised adverse prognostic factor [32–
34] and its appearance following an angiographic inter-
vention could be a predictor of later renal deterioration and
cardiovascular mortality. Therefore, the detection of pro-
teinuria has the potential to identify a high-risk sub-group
within the CIN cohort. The ERICCIN trial will, therefore,
provide biologically relevant data and provide practical
tools for monitoring patients moving through coronary
catheter laboratories.
In summary, ERICCIN is a single-centre, randomised
double-blinded placebo-controlled trial that will investigate
whether RIC can improve the rate of CIN following
iodinated contrast exposure occurring following coronary
angiographic procedures. It will follow patients for
3 months and will determine biochemical outcome data as
well as collecting data related to cardiovascular and all-
cause mortality for the duration of follow-up. The findings
will have the potential to influence a change of clinical
practice: RIC is a simple, non-invasive intervention that is
cheap to deploy in an area where there are few, if any,
effective alternatives.
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